Loading

Please wait...

Zykadia

Generic Name: ceritinib (se RI ti nib)
Brand Names: Zykadia
Zykadia (ceritinib) is used to treat metastatic non-small cell lung cancer. Includes Zykadia side effects, interactions and indications.
  • Prescription Settings
  • X

Prices and coupons of Zykadia

Set your location
for drug prices near you

Enter your zip code

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Drug Information:
Zykadia (ceritinib) is a cancer medicine that interferes with the growth and spread of cancer cells in the body. Zykadia is used to treat non-small cell lung cancer that has spread to other parts of the body. Zykadia is used only if your cancer has a specific genetic marker. Your doctor will test you for this gene. Zykadia can harm an unborn baby. Both men and women using Zykadia should use effective birth control to prevent pregnancy. Keep using birth control for at least 6 months after your last dose of ceritinib if you are a woman, or 3 months after your last dose if you are a man. Learn more

Zykadia Side Effects

Zykadia Side Effects

Note: This document contains side effect information about ceritinib. Some of the dosage forms listed on this page may not apply to the brand name Zykadia.

In Summary

Common side effects of Zykadia include: abdominal pain, diarrhea, hyperglycemia, increased serum alanine aminotransferase, nausea, and vomiting. Other side effects include: interstitial pulmonary disease, pneumonitis, and prolonged qt interval on ecg. See below for a comprehensive list of adverse effects.

For the Consumer

Applies to ceritinib: oral capsule

Along with its needed effects, ceritinib (the active ingredient contained in Zykadia) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking ceritinib:

More common

  • Blurred vision
  • burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings
  • clay-colored stools
  • dark urine
  • decreased appetite
  • dry mouth
  • fever
  • flushed, dry skin
  • fruit-like breath odor
  • headache
  • increased hunger
  • increased thirst
  • increased urination
  • loss of appetite
  • nausea
  • skin rash or itching
  • stomach pain or tenderness
  • sweating
  • swelling of the feet or lower legs
  • troubled breathing
  • unexplained weight loss
  • unsteadiness or awkwardness
  • unusual tiredness or weakness
  • vomiting
  • weakness in the arms, hands, legs, or feet
  • yellow eyes or skin

Less common

  • Chest pain
  • chills
  • cough
  • fainting
  • general feeling of discomfort or illness
  • irregular heartbeat, recurrent
  • thickening of bronchial secretions

Some side effects of ceritinib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Blurred vision or other changes in vision
  • decreased appetite
  • diarrhea
  • difficulty having a bowel movement
  • heartburn
  • pain or discomfort in the chest, upper stomach, or throat
  • seeing flashes or sparks of light

For Healthcare Professionals

Applies to ceritinib: oral capsule, oral tablet

General

The most common side effect resulting in dose reductions or interruptions were increased ALT (29%), nausea (20%), increased AST (16%), diarrhea (16%), and vomiting (16%).

The most common side effects leading to discontinuation were pneumonia, interstitial lung disease/pneumonitis, and decreased appetite.

Gastrointestinal

Very common (10% or more): Diarrhea (86%), nausea (80%), vomiting (60%), abdominal pain (54%), constipation (29%), esophageal disorder (16%)

Rare (less than 0.1%): GI hemorrhage

Hematologic

Very Common (10% or more): Hemoglobin decreased (84%), phosphate decreased (36%)

Hepatic

Very Common (10% or more): ALT increased (80%), AST increased (75%), bilirubin increased (15%)

Renal

Very Common (10% or more): Creatinine increased (58%), phosphate decreased (36%)

Metabolic

Very common (10% or more): Decreased appetite (34%), glucose increased (49%), lipase increased (28%)

Dermatologic

Very common (10% or more): Rash (16%)

Respiratory

Common (1% to 10%): Interstitial lung disease/pneumonitis

Rare (0.01% than 0.1%): Respiratory failure, pneumothorax, pulmonary tuberculosis

Nervous system

Very common (10% or more): Neuropathy (17%)

Ocular

Common (1% to 10%): Vision disorder

Cardiovascular

Common (1% to 10%): Prolonged QT, bradycardia

Rare (less than 0.1%): Cardiac tamponade

Other

Very common (10% or more): Fatigue (52%)

Uncommon (0.1% to 1%): General physical health deterioration

Immunologic

Rare (less than 0.1%): Sepsis

Editorial References and Review

Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/1/2020.

Source: Drugs.com Zykadia (www.drugs.com/zykadia.html).